Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727266 | 0.85 | METAP1 (0.42) | METAP1ATRNAMPTKDM4EL3MBTL1 | |
| SCHEMBL12310269 | 0.84 | GHSR (0.40) | METAP1ATRNAMPTKDM4EL3MBTL1 | |
| SCHEMBL1234405 | 0.81 | METAP1 (0.45) | METAP1ATRNAMPTCYP17A1RAB9A | |
| SCHEMBL1375331 | 0.81 | L3MBTL1 (0.45) | KDM4EL3MBTL1RAB9AMAP4K4TRIM24 | |
| SCHEMBL27967000 | 0.81 | RAB9A (0.49) | METAP1ATRNAMPTKDM4EL3MBTL1 | |
| SCHEMBL28110815 | 0.81 | TRIM24 (0.42) | KDM4EL3MBTL1RAB9ATRIM24TRIM33 | |
| SCHEMBL68279 | 0.81 | RAB9A (0.54) | METAP1KDM4EL3MBTL1RAB9ANPSR1 | |
| SCHEMBL15266282 | 0.81 | METAP1 (0.56) | METAP1ATRNAMPTKDM4ECYP17A1 | |
| SCHEMBL29919656 | 0.81 | RAB9A (0.54) | METAP1KDM4EL3MBTL1RAB9ANPSR1 | |
| SCHEMBL31167279 | 0.81 | ATR (0.45) | METAP1ATRNAMPTKDM4ECYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104593173-A | Detergent for grapes | YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | claimed |
| EP-4735451-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | Kumquat Biosciences Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250163079-A1 | KRAS INHIBITORS | INCYTE CORPORATION | 2025-05-22 | — | — | US | disclosed |
| WO-2025096738-A1 | KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025007000-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| EP-1226119-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1226119-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | METAP1 2540/4885ATR 4241/4885NAMPT 2079/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | METAP1 238/4885ATR 4603/4885NAMPT 3084/4885 |
| US-20250163079-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | METAP1 2534/4885ATR 767/4885NAMPT 3064/4885 |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | HRAS, KRAS, BCL6 | METAP1 2921/4885ATR 953/4885NAMPT 4807/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | METAP1 2540/4885ATR 4241/4885NAMPT 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.